Analysts Set Altimmune, Inc. (NASDAQ:ALT) PT at $20.83

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have been given a consensus rating of "Buy" by the eight analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $20.83.

ALT has been the topic of several recent research reports. UBS Group started coverage on Altimmune in a report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research report on Wednesday, January 22nd. Finally, Stifel Nicolaus started coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective on the stock.

Altimmune Stock Performance

Shares of ALT stock traded up $0.20 during mid-day trading on Friday, hitting $6.64. The company's stock had a trading volume of 1,357,619 shares, compared to its average volume of 2,202,484. The company has a market cap of $472.24 million, a PE ratio of -4.28 and a beta of 0.19. The company's fifty day simple moving average is $7.70 and its 200-day simple moving average is $7.17. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the prior year, the firm earned ($0.39) EPS. On average, equities analysts anticipate that Altimmune will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bellevue Group AG grew its position in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company's stock valued at $5,303,000 after purchasing an additional 263,660 shares during the last quarter. Virtu Financial LLC purchased a new position in Altimmune during the third quarter valued at $674,000. Barclays PLC grew its stake in shares of Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company's stock valued at $956,000 after acquiring an additional 75,064 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Altimmune by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock valued at $1,299,000 after purchasing an additional 4,772 shares during the period. Finally, Stifel Financial Corp raised its stake in Altimmune by 77.4% during the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company's stock valued at $109,000 after purchasing an additional 7,746 shares during the period. Institutional investors own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.